Cost-effectiveness and public health impact of typhoid conjugate vaccine introduction strategies in Bangladesh

Christopher Weyant, Yogesh Hooda, Sira Jam Munira, Nathan C. Lo, Theresa Ryckman, Arif M. Tanmoy, Naito Kanon, Jessica C. Seidman, Denise Garrett, Samir K. Saha, Jeremy D. Goldhaber-Fiebert, Senjuti Saha, Jason R. Andrews

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Purpose: Typhoid fever causes substantial morbidity and mortality in Bangladesh. The government of Bangladesh plans to introduce typhoid conjugate vaccines (TCV) in its expanded program on immunization (EPI) schedule. However, the optimal introduction strategy in addition to the costs and benefits of such a program are unclear. Methods: We extended an existing mathematical model of typhoid transmission to integrate cost data, clinical incidence data, and recently conducted serosurveys in urban, semi-urban, and rural areas. In our primary analysis, we evaluated the status quo (i.e., no vaccination) and eight vaccine introduction strategies including routine and 1-time campaign strategies, which differed by age groups targeted and geographic focus. Model outcomes included clinical incidence, seroincidence, deaths, costs, disability-adjusted life years (DALYs), and incremental cost-effectiveness ratios (ICERs) for each strategy. We adopted a societal perspective, 10-year model time horizon, and 3 % annual discount rate. We performed probabilistic, one-way, and scenario sensitivity analyses including adopting a healthcare perspective and alternate model time horizons. Results: We projected that all TCV strategies would be cost saving compared to the status quo. The preferred strategy was a nationwide introduction of TCV at 9–12 months of age with a single catch-up campaign for children ages 1–15, which was cost saving compared to all other strategies and the status quo. In the 10 years following implementation, we projected this strategy would avert 3.77 million cases (95 % CrI: 2.60 – 5.18), 11.31 thousand deaths (95 % CrI: 3.77 – 23.60), and save $172.35 million (95 % CrI: −14.29 – 460.59) compared to the status quo. Our findings were broadly robust to changes in parameter values and willingness-to-pay thresholds. Conclusions: We projected that nationwide TCV introduction with a catch-up campaign would substantially reduce typhoid incidence and very likely be cost saving in Bangladesh.
Original languageEnglish
Pages (from-to)2867-2876
Number of pages10
JournalVaccine
Volume42
Issue number11
Early online date2024
DOIs
Publication statusPublished - 19 Apr 2024

Keywords

  • Bangladesh
  • Cost-effectiveness
  • Enteric fever
  • Model
  • Seroincidence
  • Typhoid
  • Vaccines

Cite this